Argenx
ARGX
#567
Rank
HK$279.47 B
Marketcap
HK$4,582
Share price
-0.73%
Change (1 day)
48.72%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Cash on Hand

Cash on Hand as of December 2024 : HK$26.27 Billion

According to Argenx 's latest financial reports the company has HK$26.27 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Argenx - Cash on Hand chart (from 2021 to 2020)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31HK$26.23 B5.62%
2023-12-31HK$24.83 B44.97%
2022-12-31HK$17.13 B-5.98%
2021-12-31HK$18.22 B-4.28%
2020-12-31HK$19.03 B45.4%
2019-12-31HK$13.09 B126.3%
2018-12-31HK$5.78 B42.99%
2017-12-31HK$4.04 B387.63%
2016-12-31HK$0.82 B111.58%
2015-12-31HK$0.39 B-38.92%
2014-12-31HK$0.64 B87%
2013-12-31HK$0.34 B53.66%
2012-12-31HK$0.22 B-27.4%
2011-12-31HK$0.30 B183.15%
2010-12-31HK$0.10 B